Duopharma Biotech's newly appointed group CEO, Wan Amir-Jeffery Wan Abdul Majid
KUALA LUMPUR: Duopharma Biotech Bhd
has appointed Wan Amir-Jeffery Wan Abdul Majid as the company’s group chief executive officer (Group CEO), effective Oct 1, 2025.
Duopharma Biotech chairman Datin Paduka Kartini Abdul Manaf said Wan Amir-Jeffery has contributed immensely to the group strategically and operationally. "I am confident that Duopharma Biotech will continue its healthy growth trajectory, strengthening its position as a leading pharmaceutical company in Malaysia," she said in a statement today.
Wan Amir-Jeffery joined Duopharma Biotech in September 2016 as chief strategy officer before being promoted to chief operating officer in 2018, chief commercial officer in 2020, CEO - Commercial in 2022 and CEO - Group Operations in 2024.
He holds a Bachelor of Business Administration (International Trade) degree from the University of Central Arkansas in the United States and is an alumnus of the Senior Management Development Program of Harvard Business School.
He is also currently a vice president of the Malaysian Organisation of Pharmaceutical Industries (MOPI) for the 2025-2027 term. - Bernama
